Much hype has been granted toward a cohort of CRISPR gene editing biotechs, including the eponymous startup founded by Nobel Prize winner Emmanuelle Charpentier. But one such company has stayed relatively quiet, albeit for a subtle series A emergence in November 2020.
Now, the GV-backed startup is ready for...
